XML 45 R39.htm IDEA: XBRL DOCUMENT
v3.25.3

Segments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Summary of Segment Profit |
| a. | Segment information:
|  | Three months ended September 30, |
|  | 2025 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,483 |  |  | $ | 1,235 |  |  | $ | 557 |
Cost of sales |  |  | 996 |  |  |  | 570 |  |  |  | 280 |
R&D expenses |  |  | 161 |  |  |  | 62 |  |  |  | 26 |
S&M expenses |  |  | 278 |  |  |  | 225 |  |  |  | 122 |
G&A expenses |  |  | 114 |  |  |  | 75 |  |  |  | 36 |
Other |  |  | (3 | ) |  |  | § |  |  |  | § |
Segment profit |  | $ | 937 |  |  | $ | 303 |  |  | $ | 95 |
§ | Represents an amount less than $0.5 million.
|  | Three months ended September 30, |
|  | 2024 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,225 |  |  | $ | 1,265 |  |  | $ | 613 |
Cost of sales |  |  | 960 |  |  |  | 566 |  |  |  | 307 |
R&D expenses |  |  | 151 |  |  |  | 55 |  |  |  | 27 |
S&M expenses |  |  | 259 |  |  |  | 203 |  |  |  | 134 |
G&A expenses |  |  | 107 |  |  |  | 67 |  |  |  | 36 |
Other |  |  | § |  |  |  | 1 |  |  |  | § |
Segment profit |  | $ | 748 |  |  | $ | 373 |  |  | $ | 109 |
§ | Represents an amount less than $0.5 million.
|  | Nine months ended September 30, |
|  | 2025 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 6,543 |  |  | $ | 3,726 |  |  | $ | 1,634 |
Cost of sales |  |  | 2,748 |  |  |  | 1,687 |  |  |  | 835 |
R&D expenses |  |  | 467 |  |  |  | 181 |  |  |  | 75 |
S&M expenses |  |  | 831 |  |  |  | 652 |  |  |  | 353 |
G&A expenses |  |  | 323 |  |  |  | 210 |  |  |  | 107 |
Other |  |  | (1 | ) |  |  | § |  |  |  | (3 | )
Segment profit |  | $ | 2,175 |  |  | $ | 996 |  |  | $ | 266 |
§ | Represents an amount less than $0.5 million.
|  | Nine months ended September 30, |
|  | 2024 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 6,060 |  |  | $ | 3,749 |  |  | $ | 1,802 |
Cost of sales |  |  | 2,769 |  |  |  | 1,637 |  |  |  | 914 |
R&D expenses |  |  | 475 |  |  |  | 173 |  |  |  | 85 |
S&M expenses |  |  | 789 |  |  |  | 605 |  |  |  | 397 |
G&A expenses |  |  | 300 |  |  |  | 197 |  |  |  | 109 |
Other |  |  | (1 | ) |  |  | 1 |  |  |  | (1 | )
Segment profit |  | $ | 1,727 |  |  | $ | 1,137 |  |  | $ | 299 |
The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended September 30, 2025 and 2024:
|  | Three months ended |  |  | Nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |  |  | (U.S. $ in millions) |
United States profit |  | $ | 937 |  |  | $ | 748 |  |  | $ | 2,175 |  |  | $ | 1,727 |
Europe profit |  |  | 303 |  |  |  | 373 |  |  |  | 996 |  |  |  | 1,137 |
International Markets profit |  |  | 95 |  |  |  | 109 |  |  |  | 266 |  |  |  | 299 |
Total reportable segments profit |  |  | 1,334 |  |  |  | 1,230 |  |  |  | 3,437 |  |  |  | 3,163 |
Profit (loss) of other activities |  |  | (40 | ) |  |  | (16 | ) |  |  | (64 | ) |  |  | (1 | )
Amounts not allocated to segments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  | 144 |  |  |  | 146 |  |  |  | 436 |  |  |  | 444 |
Other assets impairments, restructuring and other items |  |  | 62 |  |  |  | (23 | ) |  |  | 272 |  |  |  | 931 |
Goodwill impairment |  |  | — |  |  |  | 600 |  |  |  | — |  |  |  | 1,000 |
Intangible assets impairments |  |  | 64 |  |  |  | 28 |  |  |  | 227 |  |  |  | 169 |
Legal settlements and loss contingencies |  |  | 60 |  |  |  | 450 |  |  |  | 309 |  |  |  | 638 |
Other unallocated amounts |  |  | 82 |  |  |  | 64 |  |  |  | 272 |  |  |  | 254 |
Consolidated operating income (loss) |  |  | 882 |  |  |  | (51 | ) |  |  | 1,857 |  |  |  | (274 | )
Financial expenses, net |  |  | 237 |  |  |  | 272 |  |  |  | 714 |  |  |  | 763 |
Consolidated income (loss) before income taxes |  | $ | 646 |  |  | $ | (324 | ) |  | $ | 1,143 |  |  | $ | (1,037 | )
Schedule Of Consolidated Income Before Income Tax | b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for the three months ended September 30, 2025 and 2024:
United States |  | Three months ended September 30, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including biosimilars) |  | $ | 1,175 |  |  | $ | 1,094 |
AJOVY ® |  |  | 73 |  |  |  | 58 |
AUSTEDO |  |  | 601 |  |  |  | 435 |
BENDEKA ® and TREANDA ® |  |  | 35 |  |  |  | 40 |
COPAXONE |  |  | 62 |  |  |  | 69 |
UZEDY |  |  | 43 |  |  |  | 35 |
Anda |  |  | 392 |  |  |  | 380 |
Other |  |  | 101 |  |  |  | 115 |
Total |  | $ | 2,483 |  |  | $ | 2,225 |
United States |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including biosimilars) |  | $ | 2,984 |  |  | $ | 2,924 |
AJOVY |  |  | 190 |  |  |  | 144 |
AUSTEDO |  |  | 1,492 |  |  |  | 1,124 |
BENDEKA and TREANDA |  |  | 111 |  |  |  | 127 |
COPAXONE |  |  | 179 |  |  |  | 179 |
UZEDY |  |  | 136 |  |  |  | 75 |
Anda |  |  | 1,130 |  |  |  | 1,134 |
Other |  |  | 321 |  |  |  | 352 |
Total |  | $ | 6,543 |  |  | $ | 6,060 |
Europe |  | Three months ended September 30, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 982 |  |  | $ | 973 |
AJOVY |  |  | 66 |  |  |  | 56 |
COPAXONE |  |  | 44 |  |  |  | 53 |
Respiratory products |  |  | 52 |  |  |  | 60 |
Other* |  |  | 91 |  |  |  | 124 |
Total |  | $ | 1,235 |  |  | $ | 1,265 |
* | Other revenues in the third quarter of 2025 and 2024 include the sale of certain product rights.
Europe |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 3,011 |  |  | $ | 2,947 |
AJOVY |  |  | 195 |  |  |  | 158 |
COPAXONE |  |  | 135 |  |  |  | 163 |
Respiratory products |  |  | 162 |  |  |  | 183 |
Other* |  |  | 223 |  |  |  | 299 |
Total |  | $ | 3,726 |  |  | $ | 3,749 |
* | Other revenues in the first nine months of 2025 and 2024 include the sale of certain product rights.
International markets |  | Three months ended September 30, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 421 |  |  | $ | 477 |
AJOVY |  |  | 30 |  |  |  | 24 |
AUSTEDO |  |  | 17 |  |  |  | 13 |
COPAXONE |  |  | 8 |  |  |  | 13 |
Other* |  |  | 82 |  |  |  | 86 |
Total |  | $ | 557 |  |  | $ | 613 |
* | Other revenues in the third quarter of 2025 and 2024 include the sale of certain product rights.
International markets |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 1,298 |  |  | $ | 1,440 |
AJOVY |  |  | 78 |  |  |  | 63 |
AUSTEDO |  |  | 34 |  |  |  | 39 |
COPAXONE |  |  | 25 |  |  |  | 38 |
Other* |  |  | 199 |  |  |  | 222 |
Total |  | $ | 1,634 |  |  | $ | 1,802 |
* | Other revenues in the first nine months of 2025 and 2024 include the sale of certain product rights.

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration